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Abstract
Background: Cystatins are inhibitors of cysteine proteases. The majority are only weak inhibitors of human
cathepsin B, which has been associated with cancer, Alzheimer’s disease and arthritis.
Results: Starting from the sequences of oryzacystatin-1 and canecystatin-1, a shuffling library was designed and a
hybrid clone obtained, which presented higher inhibitory activity towards cathepsin B. This clone presented two
unanticipated point mutations as well as an N-terminal deletion. Reversing each point mutation independently or
both simultaneously abolishes the inhibitory activity towards cathepsin B. Homology modeling together with
experimental studies of the reverse mutants revealed the likely molecular determinants of the improved inhibitory
activity to be related to decreased protein stability.
Conclusion: A combination of experimental approaches including gene shuffling, enzyme assays and reverse
mutation allied to molecular modeling has shed light upon the unexpected inhibitory properties of certain cystatin
mutants against Cathepsin B. We conclude that mutations disrupting the hydrophobic core of phytocystatins
increase the flexibility of the N-terminus, leading to an increase in inhibitory activity. Such mutations need not
affect the inhibitory site directly but may be observed distant from it and manifest their effects via an uncoupling
of its three components as a result of increased protein flexibility.
Background
The human cathepsins B and L are cysteine proteases of
the papain subfamily, which primarily function as endo-
peptidases within endolysosomal compartments. Causal
roles for cathepsins in cancer have been demonstrated
by pharmacological and genetic techniques [1], and dif-
ferent mechanisms were shown to increase the expres-
sion of cathepsins B and L in tumours [2]. Furthermore,
given the involvement of cathepsin B in neurobiological
functions and neurodegenerative disease [3], tumor pro-
gression and arthritis [2], a better understanding of its
function at the molecular level and of the mechanisms
of cathepsin inhibition is desirable.
Cystatins are a group of cysteine protease inhibitors that
have been identified in vertebrates, invertebrates, and
plants. Plant cystatins, also known as phytocystatins, are
proteins characterized by the absence of disulfide bonds
and putative glycosilation sites, which cluster in a major
evolutionary tree branch of the cystatin superfamily of
proteins [4]. In plants, phytocystatins regulate endogenous
proteolytic activities, also having a role in improving
defense mechanisms against insects and pathogens [5].
Recent studies have characterized sugarcane cystatins
[6-8], proteins that have a role in resistance to pathogenic
attacks towards sugarcane (Saccharum officinarum), a
crop extensively cultivated in Brazil due to its economic
implications as a renewable energy source [9].
The best studied phytocystatin is oryzacystatin-1 from
rice, whose fold can be described as a five-stranded anti-
parallel b-sheet wrapped around a central helix [10],
being stabilized by a hydrophobic cluster formed
* Correspondence: dfhs@power.ufscar.br; richard@if.sc.usp.br
† Contributed equally
1Center for Structural Molecular Biotechnology, Department of Physics and
Informatics, Physics Institute of São Carlos, University of São Paulo, Av.
Trabalhador são-carlense 400, 13560-970, São Carlos-SP, Brazil
2Laboratory of Molecular Biology, Department of Genetic and Evolution,
Federal University of São Carlos, Rodovia Washington Luis km 235, CEP
13565-905, São Carlos-SP, Brazil
Full list of author information is available at the end of the article
Valadares et al. BMC Structural Biology 2010, 10:30
http://www.biomedcentral.com/1472-6807/10/30
© 2010 Valadares et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
between the two which contains a specific LARFAV-like
conserved sequence present only in phytocystatins [4].
Cystatins use three structural elements to interact and
inhibit cysteine proteases, two loops together with the
N-terminal region. Both loops physically interact with
the active site of the cysteine protease, the first through its
QXVXG motif (residues Q53 to G57 in oryzacystain-1)
and the second via residues P83 and W84. The
N-terminal region does not directly interact with the
active site, but makes extensive contacts with the pro-
tease, playing an important role in the binding process
[10-12].
Here, we describe the use of DNA shuffling to create a
new hybrid cystatin with improved cathepsin B inhibi-
tory activity, obtained through the recombination of
canecystatin-1 and oryzacystatin-1. The activity and
physicochemical properties of three other mutants
obtained through the reversion of point mutations
observed in this hybrid, as well an N-terminally deleted
version of oryzacystatin, were also determined. Analysis
of molecular models of these recombinant proteins was
used to explain the molecular determinants of their
activities.
Methods
DNA shuffling library construction
The method used involves the fragmentation of genes
with similar DNA sequences using DNase I to generate
a pool of random DNA fragments. These fragments
were reassembled into a full-length gene by repeated
cycles of annealing in the presence of DNA polymerase.
The fragments prime on each other based on sequence
homology, and recombination occurs when fragments
from one gene anneal to fragments from the other,
causing a template switch.
Gene Selection
The choice of specific genes encoding counterpart
cysteine protease inhibitors in sugarcane (CaneCPI-1,
[GenBank:AY119689]) and rice (oryzacystatin I, [Gen-
Bank:U54702]) was based on the similarity of their DNA
sequences (56%).
Substrate Preparation
The principle of DNA shuffling is recombining distinct
genes that present high similarity in their DNA
sequence. In our case, the selected genes CaneCPI-1
and OC-I were used in the construction of the shuffling
library. The substrates used for the shuffling reactions
were PCR products obtained from the amplification of
the CaneCPI-1 and OC-I genes using the pET28aCa-
neCPI-1 [6] and pET28OC-I [13] plasmids respectively,
as templates. For CaneCPI-1 amplification by PCR the
following primer sequences were employed: CaneCPI-1F
(5´ TCGAAGGTCGTCATATGATGGCCGAGGCAC
3´) and T7 terminator (5´ TAGTTATTGCTCAGC
GGTGG 3´). In the case of the OC-I gene the primer
T7 promoter (5´ TAATACGACTCACTATAGGG 3´)
together with the T7 terminator primer were used. Free
primers from the PCR product were removed by Wizard
PCR (Promega).
DNAse I Digestion
About 4 μg of amplification product (DNA substrate)
were digested with 0.15 unit of DNAse I (10U/μl)
in 100 μl of buffer containing 50 mM Tris-HCl, pH 7.4,
1 mM MnCl2, for 10-20 min at room temperature. Frag-
ments of 40-120 bp were recovered from 2% low melt-
ing point agarose gels by electrophoresis using the gel
Kit QIAEX II Agarose Gel Extraction (QIAGEN) and
ethanol precipitated.
PCR without primer
The recovered fragments of 40-120 bp obtained from
DNase I digestion were used in the reaction of recombi-
nation. The first extension was performed using 5 μl of
each purified fragment and re-suspended in 20 μl of
PCR mixture containing 0.2 mM each dNTPs, 1.5 mM
MgCl2, 0.1 μl Taq DNA Polymerase (5U/μl), 0.1 μl Pfu
Turbo DNA Polymerase (2.5 U/μl) and 2 μl Taq buffer
10×. This solution was submitted to a round of exten-
sion of 40 cycles at 95°C/30 sec, 50°C/30 sec, 72°C/2
min + 2 sec/cycle.
PCR with Primers
8 μl of recombination product obtained from PCR with-
out primers were used in 100 μl of PCR mixture with
0.2 mM dNTPs, 10 μl of amplification buffer (10×), 3 μl
MgCl2 (50 mM), 2 μl first OC-I forward primer
(10 pmol/μl) and CaneCPI-1 reverse primer (10 pmol/μl),
2.5 U of Taq DNA Polymerase. The conditions for ampli-
fication were: 1× [94°C/1 min], 35× [94°C/1 min, 47°C/1
min and 72°C/1.5 min] and 1× [72°C/5 min]. The ampli-
fication product was submitted to analysis by agarose gel
electrophoresis and amplified DNA was purified from the
gel using the QIAEX II gel extraction kit (QIAGEN).
Cloning and Analysis
The plasmid pET28a was cut with Eco RI and Nde I and
dephosphorylated with shrimp alkaline phosphatase
(SAP) in 5 μl buffer containing 200 mM Tris pH 8.0 and
100 mM MgCl2; 1 μl SAP (1U/μl) and water to 50 μl for
an incubation of 1 hour at 37°C. The inactivation of SAP
was performed at 70°C for 20 min. This solution was pre-
cipitated with ethanol and re-suspended in water to a
final volume of 30 μl. The products of final amplification
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were digested with the restriction enzymes Eco RI and
Nde I and ligated in the dephosphorylated pET28a plas-
mid. The ligation reaction was used to transform E. coli
Rosetta (DE3), for expression of the hybrid proteins.
About 2000 clones were sequenced by the dideoxy
method [14] using an ABI Prism 377 (Applied Biosys-
tems). The sequences obtained were then analyzed using
BLAST alignments and the software Multalin http://
bioinfo.genotoul.fr/multalin/multalin.html in order to
find a clone resulting from recombination. Based on the
recombinants obtained several clones were selected and
submitted to expression analysis and subsequent inhibi-
tory activity assays.
Site-directed mutagenesis
Site-directed mutagenesis was performed using the Gene
Tailor™Site Directed Mutagenesis System (Invitrogen).
The pET28a encoding the mutant A10 gene was used as
template DNA for the construction of the reverse mutant
1 (T30I) and mutant 2 (Q97L). The DNA corresponding
to mutant 2 was used as a template for the construction of
reverse mutant-3 (the double mutant) using the mutant-1
primers to allow for both mutations. The primer




GAGCTTCAG-3´; mutant-2 reverse, 5´-CCACACCCT
CTTGAAGTTCGTC-3´. PCR products were analyzed on
agarose gels to confirm the presence of a product of the
correct molecular weight and all plasmids were sequenced.
The recombinant cystatins were expressed in E. coli
Rosetta (DE3) carrying the appropriate pET28a vector,
and purified as previously described [6,8].
Expression of recombinant cystatins and mutants
Two clones of the shuffling library were selected for this
study. One of these, here termed OC-I NΔ, was a pure
oryzacystatin clone which presented a seven-residue N-
terminal deletion. The second was a hybrid clone con-
taining two mutations besides the N-terminal deletion
(clone A10). These clones were selected for expression
and inhibition assays together with OC-1, CaneCPI-1,
CaneCPI-4, and the mutant 1, 2, and 3. The correspond-
ing constructs were used to transform competent strains
of E. coli Rosetta (DE3) with calcium chloride. The
transformed cells were cultivated at 37°C under agitation
in selective medium containing kanamycin (25 mg/mL)
until they reached an optical density (O.D.) of 0.6, at
600 nm, when protein expression was induced by the
addition of IPTG to a final concentration of 0.4 mM.
Aliquots were taken for up to 4 h (at 1 hour intervals)
after induction and the cell extract was analyzed on
SDS-PAGE 15% [15]. After induction, the cells were
collected, centrifuged, and subjected to a solubility test.
To this end, the cells were suspended in suspension buf-
fer containing 10 mM Tris-HCl, 100 mM NaCl, 50 mM
NaH2PO4, pH 8.0 and subjected to lyses by sonication
five times for 1 min at 30 s intervals. The lysed cells
were centrifuged at 13,000 g and 4°C for 10 min, and
the supernatant and precipitate analyzed on SDS-PAGE
15% [15].
Purification of the recombinant proteins
The fraction containing the soluble proteins was purified
from the supernatant using a nickel affinity column,
Ni-NTA superflow (Qiagen). The column was equili-
brated and washed with two column volumes of suspen-
sion buffer and after sample application the proteins
were eluted with increasing imidazol concentrations (10,
25, 50, 75, 100, and 250 mM). The purified proteins
were analyzed on SDS-PAGE 15%. The fractions con-
taining the purified proteins were dialyzed using
MWCO: 3 membranes (Spectrum Laboratories) and the
concentrations determined by Bradford’s method [16].
Enzyme inhibition activity
The inhibitory activity of the recombinant cystatins was
measured against human cathepsins B and L (Calbio-
chem) using the fluorogenic substrate Z-Phe-Arg-MCA
(Calbiochem) as previously described [8]. Briefly, human
cathepsins B and L (0.3 nM) were individually incubated
for 5 min at 37°C with different inhibitors CaneCPI-1,
OC-I, OC-I NΔ, A10, mutant 1, mutant 2 and mutant 3
in a buffer containing 100 mM sodium acetate pH 5.5,
2.5 mM DTT. The concentration range of each inhibitor
is presented in Additional file 1. The substrate Z-Phe-
Arg-MCA (0.01 mM) was added and the residual hydro-
lytic activity was monitored using a Hitachi F-2500
spectrofluorometer (lex = 380 nm and lem = 460 nm).
All experiments were carried out in triplicate and the
results used to determine Ki(app) by non linear regression
using the GraFit program [17]. The equilibrium inhibi-
tion constant (Ki) of the enzyme inhibitor complex was
subsequently calculated using Morrison’s procedure
[18,19].
Molecular Modeling
The amino acid sequences of oryzacystatin-1 and human
stefin B were retrieved from Swiss-Prot (accession num-
bers [Swiss-Prot:P09229] and [Swiss-Prot:P04080],
respectively) and the three-dimensional structures were
obtained from the protein databank (1EQK and 1STF,
respectively). The sequences were aligned using CLUS-
TALX http://www.clustal.org/download/current/ and the
result manually adjusted based on structural superposi-
tion. The sequences of the cystatins were then aligned
to this template.
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Comparative molecular models corresponding to each
of these alignments were obtained using the program
MODELLER 9v8 [20]. A series of different models were
generated and their quality evaluated by the MODEL-
LER pseudo-energy term and its DOPE score [21]. The
models were also subjected to independent evaluation
by the programs VERIFY 3D [22] and WHATIF [23],
and a representative model for structural analysis was
selected.
Results and Discussion
A total of two thousand clones were sequenced from the
shuffling library. Amino acid sequence analyses were
made in order to find a hybrid formed by the CaneCPI-I
and OC-I proteins. It was expected that the DNA
encoding two distinct but similar proteins would form a
heteroduplex hybrid, but in practice most of the ana-
lyzed clones in the library were homoduplex. Approxi-
mately 50% and 25% of clones were identical to OC-I
and CaneCPI-1, respectively. A further 20% corre-
sponded to OC-I with the N-terminal deletion (OC-I
NΔ) and the remaining 5% were shuffled, truncated or
presented point mutations. From among the many
clones OC-I NΔ and A10, the latter belonging to the
remaining 5%, were selected to be of potential interest.
Expression and purification assays for OC-I, CaneCPI-1,
CaneCPI-4, OC-I NΔ, A10, mutant 1, mutant 2 and
mutant 3 was performed and analyzed in a Coomassie
blue stained SDS-PAGE (Figure 1). This analysis revealed
the presence of the His-tagged proteins of expected sizes
for the induced clones, the insoluble and soluble fractions,
and the purified recombinant protein. Most of the recom-
binant proteins were in their soluble form and could be
purified directly by affinity chromatography on a nickel
column using 250 mM imidazole. Even CaneCPI-4, A10
and mutant 1, which presented high amounts of protein in
the insoluble fraction, could be purified from the superna-
tants. The amounts of pure recombinant proteins obtained
after a single step of purification were sufficient for per-
forming activity tests.
The cysteine peptidases cathepsin L and B were
assayed in the presence of the recombinant cystatins.
Their inhibitory activity was assessed in a fluorometric
assay using Z-Phe-Arg-MCA as substrate for which
cathepsin L and B present KM values of 2 μM and 23.4
μM, respectively [24]. The residual hydrolytic activity of
the enzyme was measured after pre-incubation for
5 minutes with the inhibitors at different concentrations.
The resulting Ki values are shown in Table 1.
Two clones in particular (OC-I NΔ and A10) presented
interesting profiles in terms of enzyme inhibition. The
majority of cystatins, such as oryzacystatin-1 (from which
OC-I NΔ was derived) and canecystatin-1, bind more
tightly to cathepsin L than to cathepsin B, and typically
show at least one order of magnitude difference in terms
of Ki. OC-I NΔ, on the other hand, presented no activity
towards Cathepsin B whilst still retaining moderate activ-
ity towards cathepsin L. A completely different profile
was shown by A10 which presented comparable inhibi-
tion of both enzymes due to an increased activity towards
Cathepsin B (Ki = 11.21 nM, see Table 1).
Four differences can be noted between A10 and the
original canecystatin-1 from which it is largely derived.
Firstly, the N-terminal region of A10 comes from oryza-
cystatin-1 and not canecystatin-1, a result of the gene
shuffling process itself. Secondly, this region has suffered
a 7 amino acid deletion (Figure 2). Finally, A10 has
acquired two unexpected point mutations affecting
hydrophobic residues of the protein core, I30T at the
beginning of the a-helix and L97Q in strand b5 (residue
numbers follow those of canecystatin-1 throughout the
text unless otherwise stated, see Figure 2).
Table 1 also shows data on enzyme inhibition by
mutants in which these specific peculiarities of A10 were
individually dissected. A deletion mutant of oryzacysta-
tin-1 which reproduces the effect of the loss of seven
residues towards the N-terminus of A10, retained nano-
molar activity towards cathepsin L, but lost all of its
activity towards Cathepsin B. This is consistent with the
current model for cathepsin B inhibition by cystatins in
which initial binding of the N-terminal region precedes a
conformational change to the occluding loop [25,26].
Changes to this region are known to significantly affect
inhibitory activity towards cathepsin B, and the residues
lost as a consequence of the deletion have been identified
as important for protease binding [12]. It is therefore not
entirely unexpected that the two reverse mutants of A10
(T30I and Q97L), which also present the 7-residue dele-
tion, were also unable to significantly inhibit Cathepsin
B. On the other hand both retained their ability to inhibit
Cathepsin L at the nMolar level, indicative of correct
folding. What is more surprising is the ability of A10
itself to inhibit cathepsin B at all. The accumulation of
the two mutations together is somehow able to overcome
the deleterious effect of the N-terminal deletion and to
turn A10 into a nMolar inhibitor of cathepsin B.
3.3. Sequences and molecular homology models analysis
A homology model for the canecystatin-1 structure
shows that, unlike a similar model for clone A10, it pre-
serves the hydrophobic core seen in oryzacystatin-1
[10]. This is located at the interface between the five-
stranded anti-parallel b-sheet and the single a-helix
(Figure 3). In the b-sheet of canecystatin-1, the residues
involved in this interface are M47, L48, F50, L53, V56
(in strand b2), F68, V70, V72 (strand b3), Y82, A84,
V86 (strand b4) and L97, F100 (strand b5). The clone
A10 presents a glutamine residue instead of a leucine in
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Figure 1 Expression and purification of phytocystatins and mutants. SDS-PAGE 15% stained with Coomassie blue showing OC-I, CaneCPI-1,
CaneCPI-4, OC-I NΔ, A10, mutant 1, mutant 2 and mutant 3. Samples were collected and analyzed in SDS-PAGE 15%. In (1) molecular mass
marker; (2) E. coli Rosetta (DE3) cell extract before and (3) after IPTG induction, (4) insoluble and (5) soluble fractions after disruption of induced
cells from E. coli Rosetta (DE3), and (6) purified recombinant protein after elution with 250 mM imidazole from a nickel column.
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the position 97 (Figure 3). Close to the N-terminus of
the helix there is a small strand (b1) which interacts
with b2 via both main chain hydrogen-bonds as well
as hydrophobic contacts involving A21 and V56, the
latter on strand b2. The helix residues most obviously
involved in the hydrophobic core are I30 and the resi-
dues of the conserved LARFAV sequence. The remark-
able conservation of this motif among phytocystatins
has been emphasized previously, but the authors were
unable to attribute to it a specific functional role [27].
We propose that the role of this motif is to provide
ideal complementarity to the hydrophobic residues in
the b-sheet of the phytocystatins, essential for stabilizing
the tertiary structure.
The three active site segments of phytocystatins which
directly interact with the binding pocket of the enzyme
have been proposed based on the complex formed
between stefin B and papain [10,11]. The first interact-
ing loop corresponds to canecystatin-1 residues 59-63,
presenting the highly conserved sequence QVVAG,
which is identical in oryzacystatin-1 and A10. The
second binding loop includes V90 and W91 (P 83 and
W84 in oryzacystatin-1) and the third interaction site is
formed by the N-terminal region.
These three regions form the classical interaction sur-
face between cystatins and cysteine proteinases. How-
ever, Cathepsin B, different from Cathepsin L and most
other cysteine proteinases, possesses a large insertion
(the occluding loop) which covers part of the binding
pocket thus impeding the simultaneous entry of all
three elements of the inhibitor’s active site. The
observed binding of some cystatins to Cathepsin B is
explained by a two-step mechanism in which the initial
binding of the N-terminal region leads to subsequent
displacement of the occluding loop generating an effec-
tive binding mode [25,26]. Furthermore, recent studies
employing single mutations at positively selected amino
acid sites confirm the functional importance of the
N-terminal region of phytocystatins [27,28]. Here we
show that the N-terminal deletion mutant and the dou-
ble reverse mutant, both of which present the 7 residue
deletion near the N-terminus, are unable to inhibit
cathepsin B. On the other hand the two point mutations
which restore activity to A10 are located distant from
the active site loops and therefore must influence activ-
ity via an indirect effect.
As depicted in Figure 4A, the first mutation (I30T) is
located at the beginning of the a-helix where it would
be expected to destabilize the hydrophobic cluster
formed by residues F50, L53, I30 the aliphatic portion of
R34 and the loop connecting the N-terminus to the a-
helix (Additional file 2). The second mutation (L97Q)
appears yet more significant and perturbs the opposite
side of the hydrophobic core formed by L32, F35, A36,
V86, F100 and L97 (Figure 4B). We suggest that these
mutations would significantly destabilize the hydropho-
bic contacts which hold the helix against the b-sheet,
thus leading to its complete or partial release. This
Table 1 Inhibition of cathepsins B and L by cystatinsa
Cystatin Ki
Cathepsin B Cathepsin L
Oryzacystatin-1 78.5 nM 0.73 nM
Canecystatin-1 87.6 nM 0.10 nM




Clone A10 11.2 nM 1.63 nM
Reverse Mutant 1 (T30I) NI 1.93 nM
Reverse Mutant 2 (Q97L) NI 11.7 nM
Reverse Mutant 3 (T30I, Q97L) NI 12.5 nM
a NI indicates no inhibitory activity observed at the highest concentration of
the inhibitor employed.
b data previously published [8].
Figure 2 Sequence alignment of relevant cystatins. Sequence alignment between oryzacystain-1 (cyan), canecystatin-1 (green), A10 and
canecystatin-4. Conserved amino acids are show in red. Residues conserved in all sequences except canecystatin-4 are coloured in yellow. In the
case of the clone A10 the residues are shaded according to the cystatin from which they were derived with point mutations shaded in purple,
and the N-terminal deletion from residues 11 to 19 is shown as a blue gap. The clone OC-I NΔ has the sequence of oryzacystatin-1, but with the
same N-terminal deletion as the clone A10.
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Figure 3 The hydrophobic core residues arising from the anti-parallel b-sheet of clone A10. The transparent cartoon shows the three-
dimensional fold of the protein in blue, and the residues participating in the hydrophobic core are colored in orange. Threonine 30 (from the
a-helix) and glutamine 97 are coloured in green.
Figure 4 Homology model of clone A10 showing the residues correspondent to the point mutations. Interactions of (A) threonine 30
(magenta) and (B) glutamine 97 (orange). Interacting residues are labeled and shown as spheres. It is likely that the mutations would
significantly destabilize the hydrophobic core leading to a conformation different to that shown in the figure.
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release would have the effect of decoupling two compo-
nents of the inhibitor active site; the N-terminal region
on the one hand and the remaining two loops on the
other.
The increased flexibility of the N-terminal region in
the A10 mutant may allow it to regain its role in the
initial binding to the enzyme as the first step in the well
established two step mechanism. Alternatively, the
uncoupling of the three components of the inhibitor
active site may reduce steric hindrance and facilitate
direct binding by the QVVAG and VW loops to the
catalytic site.
It is noteworthy that the observation of three-dimen-
sional domain swapping within the cystatin family
involves exactly the type of structural rearrangement
that we are proposing here [29]. This allows cystatins to
self assemble into different oligomeric states [30,31] and
even form amyloid fibrils [32,33]. Thus it would seem
that perturbation of the hydrophobic contacts between
these secondary structure elements could readily lead to
destabilization of this interface. This hypothesis is
further supported by the observation that A10 is much
less soluble than the parent molecules and tends to
aggregate in inclusion bodies when heterologously
expressed (Figure 1), consistent with the exposure or
partial exposure of its hydrophobic core. The single
reverse mutants show intermediate solubilities, with the
T30I mutant (which retains the glutamine at position
97) being the less soluble of the two. However, the inhi-
bition data on these mutants demonstrates that both
mutations are necessary for the increased activity of A10
towards cathepsin B.
Although A10 still presents a lower activity towards
cathepsin B than other natural cystatins such as its endo-
genous inhibitor cystatin C, the hypothesis raised here
presents a rational basis which might be exploitable in
the development of tighter binding cathepsin B inhibi-
tors. In this context it is worth mentioning that sugar
cane expresses several such inhibitors besides canecysta-
tin-1. For example canecystatin-4 has been reported to
have an affinity comparable to that of cystatin C [8,25].
Figure 2 shows that canecystatin-4 also presents interest-
ing variations to some of the hydrophobic residues at the
interface between the helix and the b-sheet, including a
glutamine at position 30 (corresponding to one of the
positions mutated in A10) and glycines at positions 47
and 56, which decrease the volume of the hydrophobic
core. Furthermore it has been reported that canecystatin-
4 tends to aggregate more readily than canecystatin-1 [8].
In summary, it is hoped that the methodology and
structural insights presented here can be useful in the
design of more potent and specific cathepsin inhibitors,
as well as contributing to the rationalization of the
activity of already characterized cystatins. Specifically,
mutations outside the N-terminal region which lead to
an altered mobility may be an interesting alternative
approach compared with modifying the region itself.
Conclusions
A combination of experimental approaches including
gene shuffling, enzyme assays and reverse mutation has
been used to better understand the inhibitory properties
of cystatin mutants against Cathepsin B. Molecular
modeling of the mutant enzymes suggests that disrup-
tion of the hydrophobic core may lead to an increase in
the flexibility of the N-terminus, and consequently an
increase in inhibitory activity. Such mutations need not
affect the inhibitory site directly, but may be observed
distant from it and manifest their effects via an uncou-
pling of its three components as a result of increased
protein flexibility.
Additional material
Additional file 1: Additional Table S1. Concentrations of the different
inhibitors used in the enzyme inhibition assays for cathepsins B and L.
Additional file 2: Video: Molecular modeling of the Canecystatin-1.
The hydrophobic cluster formed by residues Phe50, Leu53, Ile30 the
aliphatic portion of Arg34 and the loop connecting the N-terminus to
the α-helix. Ile30 is coloured in magenta, and is mutated to threonine in
the clone A10.
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